-
1 Comment
Hualan Biological Engineering Inc is currently in a long term downtrend where the price is trading 17.5% below its 200 day moving average.
From a valuation standpoint, the stock is 51.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 14.6.
Hualan Biological Engineering Inc's total revenue rose by 83.7% to $2B since the same quarter in the previous year.
Its net income has increased by 103.0% to $649M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.4% to $616M since the same quarter in the previous year.
Based on the above factors, Hualan Biological Engineering Inc gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000001JN8 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 26B |
|---|---|
| Beta | 0.45 |
| Target Price | 18.446 |
| Dividend Yield | 0.0% |
| PE Ratio | 27.81 |
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002007.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
